Bill > SB253

This bill, effective August 1, 2026, enacts a new law, R.S. 37:23.5, to regulate peptides by preventing professional and occupational licensing boards from prohibiting healthcare providers with prescriptive authority from prescribing peptides. These peptides must be shipped from either a FDA-registered 503B outsourcing facility, which is a type of drug manufacturing facility that prepares sterile drug products for use in healthcare settings and must comply with specific federal regulations (21 U.S.C. 353b), or a 503A compounding pharmacy, which is a pharmacy that compounds medications for individual patients based on a prescription and must adhere to federal guidelines (21 U.S.C. 353a) and relevant United States Pharmacopeia - National Formulary (USP-NF) chapters, which are official standards for drug quality. Additionally, the bill ensures that Louisiana-licensed pharmacists in pharmacies permitted by the state can compound and dispense peptides, provided they also comply with the same federal regulations and USP-NF chapters as 503A compounding pharmacies.